Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 33

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 33
---
 amounts related to royalties from our collaboration agreements.

As of June 30, 2025, total liabilities were $1,162 million compared to $1,277 million on December 31, 2024. The decrease in total liabilities of $115 million was primarily driven by a decrease of $199 million in corporate taxes payable primarily due to Genmab’s lower annual effective tax rate, partially offset by an increase in current other payables of $78 million, primarily related to accruals related to the expansion of our product pipeline, offset by a decrease in accrued compensation due to bonus payments made in the first three months of 2025.

Shareholders’ equity as of June 30, 2025, was $5,302 million compared to $5,137 million on December 31, 2024. The increase of $165 million, or 3%, was primarily driven by Genmab’s net profit for the period and share-based compensation expenses, partly offset by the purchase of treasury shares. Genmab’s equity ratio increased to 82% as of June 30, 2025 compared to 80% as of December 31, 2024.

Team Members As of June 30, 2025, the total number of team members was 2,639 compared to 2,526 as of June 30, 2024. The increase was primarily driven by the continued expansion of our product portfolio, as well as the investment in the expansion of Genmab’s global commercialization capabilities, including continued support for EPKINLY in the U.S. and Japan post launch activities, and broader organizational capabilities and the acquisition of ProfoundBio, which occurred during the second quarter of 2024.

|                                                  |     | Six Months Ended June 30, |       |     |      |       |
| Team Members                                     |     |                      2025 |       |     | 2024 |       |
| Research and development team members            |     |                           | 1,830 |     |      | 1,774 |
| Selling, general and administrative team members |     |                           |   809 |     |      |   752 |
| Total team members                               |     |                           | 2,639 |     |      | 2,526 |

#### Legal Matters

#### Chugai Patent Infringement Complaint
In 2024, Chugai filed a lawsuit in the Tokyo District Court, Japan against AbbVie’s and Gen